Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Trial Details

NCT ID

NCT03096418

Phase

PHASE4

Sponsor

University of Wisconsin, Madison

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Paclitaxel

Locations (sample)

Iowa City, Iowa, United States|41.66113,-91.53017
Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

Women with pathologically demonstrated breast cancer
Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist. No other investigational or commercial therapeuti…
Patients must not have metastatic disease on staging work-up per institutional guidelines.
A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor (preferre…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →